Parainfluenza virus 5 based vaccines
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorBiao He
Life of this patent
Estimating the term…
Abstract
The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.
Claims30
A viral expression vector comprising a parainfluenza virus 5 (PIV5) genome comprising a heterologous nucleotide sequence expressing a heterologous polypeptide, wherein the heterologous nucleotide sequence replaces the small hydrophobic (SH) gene nucleotide sequence of the PIV5 genome, and wherein the heterologous polypeptide is not derived from mumps virus.
A viral expression vector comprising a parainfluenza virus 5 (PIV5) genome comprising a heterologous nucleotide sequence expressing a heterologous polypeptide, wherein the heterologous nucleotide sequence replaces the SH gene nucleotide sequence of the PIV5 genome, wherein the PIV5 genome further comprises one or more mutations, and wherein the mutation comprises PIV5VΔC.
Dependencies are inferred from the claim text.